Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa.
BMC Infect Dis. 2010 Mar 30;10:83. doi: 10.1186/1471-2334-10-83.
HIV-1 and Mycobacterium tuberculosis cause substantial morbidity and mortality. Despite the availability of antiretroviral and antituberculosis treatment in Africa, clinical deterioration during antituberculosis treatment remains a frequent reason for hospital admission. We therefore determined the incidence, causes and risk factors for clinical deterioration.
Prospective cohort study of 292 adults who initiated antituberculosis treatment during a 3-month period. We evaluated those with clinical deterioration over the following 24 weeks of treatment.
Seventy-one percent (209/292) of patients were HIV-1 infected (median CD4+: 129 cells/microL [IQR:62-277]). At tuberculosis diagnosis, 23% (34/145) of HIV-1 infected patients qualifying for antiretroviral treatment (ART) were receiving ART; 6 months later, 75% (109/145) had received ART. Within 24 weeks of initiating antituberculosis treatment, 40% (117/292) of patients experienced clinical deterioration due to co-morbid illness (n = 70), tuberculosis related illness (n = 47), non AIDS-defining HIV-1 related infection (n = 25) and AIDS-defining illness (n = 21). Using HIV-1 uninfected patients as the referent group, HIV-1 infected patients had an increasing risk of clinical deterioration as CD4+ counts decreased [CD4+>350 cells/microL: RR = 1.4, 95% CI = 0.7-2.9; CD4+:200-350 cells/microL: RR = 2.0, 95% CI = 1.1-3.6; CD4+<200 cells/microL: RR = 3.0, 95% CI = 1.9-4.7]. During follow-up, 26% (30/117) of patients with clinical deterioration required hospital admission and 15% (17/117) died. Fifteen deaths were in HIV-1 infected patients with a CD4+<200 cells/microL.
In multivariate analysis, HIV-1 infection and a low CD4+ count at tuberculosis diagnosis were significant risk factors for clinical deterioration and death. The initiation of ART at a CD4+ count of <350 cells/microL will likely reduce the high burden of clinical deterioration.
HIV-1 和结核分枝杆菌会导致大量的发病率和死亡率。尽管在非洲有抗逆转录病毒和抗结核治疗,但在抗结核治疗期间临床恶化仍然是住院的常见原因。因此,我们确定了临床恶化的发生率、原因和危险因素。
前瞻性队列研究了 292 名在 3 个月期间开始抗结核治疗的成年人。我们评估了在接下来的 24 周治疗期间临床恶化的患者。
71%(209/292)的患者感染了 HIV-1(中位数 CD4+:129 个细胞/微升[IQR:62-277])。在诊断结核分枝杆菌感染时,符合抗逆转录病毒治疗(ART)条件的 23%(34/145)HIV-1 感染患者正在接受 ART;6 个月后,75%(109/145)接受了 ART。在开始抗结核治疗的 24 周内,292 名患者中有 40%(117/292)因合并疾病(n=70)、与结核分枝杆菌相关的疾病(n=47)、非艾滋病定义的 HIV-1 相关感染(n=25)和艾滋病定义的疾病(n=21)而出现临床恶化。以未感染 HIV-1 的患者为参照组,随着 CD4+计数的降低,HIV-1 感染患者发生临床恶化的风险逐渐增加[CD4+>350 个细胞/微升:RR=1.4,95%CI=0.7-2.9;CD4+=200-350 个细胞/微升:RR=2.0,95%CI=1.1-3.6;CD4+<200 个细胞/微升:RR=3.0,95%CI=1.9-4.7]。在随访期间,117 例临床恶化患者中有 26%(30/117)需要住院治疗,15%(17/117)死亡。15 例死亡发生在 CD4+<200 个细胞/微升的 HIV-1 感染患者中。
在多变量分析中,HIV-1 感染和结核分枝杆菌诊断时的低 CD4+计数是临床恶化和死亡的显著危险因素。在 CD4+计数<350 个细胞/微升时开始 ART 治疗可能会降低临床恶化的高负担。